產品詳情
查看大圖

  • 產品名稱：CRL-1751 WEHI 164 小鼠纖維肉瘤細胞係

  • 產品型號：CRL-1751
  • 產品廠商：其它品牌
  • 產品文檔：
你添加了1件商品 查看購物車
簡單介紹：
簡單介紹 CRL-1751 WEHI 164 小鼠纖維肉瘤細胞係，原代細胞|細胞係|細胞株|菌種；細胞庫管理規範，提供的細胞株背景清楚，提供參考文獻和**培養條件！
詳情介紹：

CRL-1751 WEHI 164 小鼠纖維肉瘤細胞係 的詳細介紹
CRL-1751 WEHI 164 小鼠纖維肉瘤細胞係
ATCC® Number: CRL-1751™    Price:
Designations: WEHI 164
Depositors:  TW LeBien
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Mus musculus (mouse)
Morphology: fibroblast
Source: Disease: fibrosarcoma
Strain: BALB/c
Cell Type: methylcholanthrene induced
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Comments: This line was originally established by M. Rollinghoff and N.L. Warner from a fibrosarcoma induced by subcutaneous injections of 3-methylcholanthrene.
After pretreatment with actinomycin D, the cells are highly sensitive to human cytotoxic monocytes, to human tumor necrosis factor and to lymphotoxin.
They can be used as target cells for short term chromium release cytotoxicity assays.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:5 to 1:20 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, add fresh 0.25% trypsin, 0.02% EDTA solution for 1 to 2 minutes. Remove trypsin and place the flask at 37C until the cells detach (about 3 to 5 minutes). Add fresh medium, aspirate and dispense into new flasks.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1760: Ziegler-Heitbrock HW, Riethmuller G. A rapid assay for cytotoxicity of unstimulated human monocytes. J. Natl. Cancer Inst. 72: 23-29, 1984. PubMed: 6582301
1761: Ziegler-Heitbrock HW, et al. Killer cell activity of human monoblastic leukemia cells as detected with a monocyte-specific target cell. Blood 65: 8-14, 1985. PubMed: 3155490
21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111
23194: Rollinghoff M, Warner NL. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells. Proc. Soc. Exp. Biol. Med. 144: 813-818, 1973. PubMed: 4543620
32697: Knowlton KU, et al. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the woodruff variant of coxsackievirus B3. J. Virol. 70: 7811-7818, 1996. PubMed: 8892902


滬公網安備 31010902002433號